NCT05155215 2021-12-13
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
Beijing Immunochina Medical Science & Technology Co., Ltd.
RenJi Hospital
Istituto Clinico Humanitas
Targazyme, Inc.
Samsung Medical Center